# TMC278-TiDP6-C153 - A Study in Healthy Volunteers Investigating the Pharmacokinetic Interaction Between TMC278 and Raltegravir

> **NCT01288755** · PHASE1 · COMPLETED · sponsor: **Tibotec Pharmaceuticals, Ireland** · enrollment: 24 (actual)

## Conditions studied

- HIV Infections

## Interventions

- **DRUG:** TMC278
- **DRUG:** Raltegravir

## Key facts

- **NCT ID:** NCT01288755
- **Lead sponsor:** Tibotec Pharmaceuticals, Ireland
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2011-02
- **Primary completion:** —
- **Final completion:** 2011-05
- **Target enrollment:** 24 (ACTUAL)
- **Last updated:** 2011-06-27

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01288755

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01288755, "TMC278-TiDP6-C153 - A Study in Healthy Volunteers Investigating the Pharmacokinetic Interaction Between TMC278 and Raltegravir". Retrieved via AI Analytics 2026-06-01 from https://api.ai-analytics.org/clinical/NCT01288755. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*